Oculis to Unveil Phase 2 Data for Privosegtor at NANOS Meeting
Event summary
- Oculis will present Phase 2 ACUITY trial data for Privosegtor at the NANOS 52nd Annual Meeting on March 23, 2026.
- Privosegtor showed improvements in low-contrast visual acuity and reduction in retinal ganglion cell loss in optic neuritis patients.
- Oculis is a Platinum Sponsor of the NANOS 2026 Congress, reinforcing its commitment to neuro-ophthalmology.
- Privosegtor has received Breakthrough Therapy designation from the FDA and Orphan Drug designation from both the FDA and EMA for optic neuritis.
The big picture
Oculis' presentation at the NANOS meeting underscores the growing focus on neuroprotective therapies in ophthalmology. The Phase 2 data for Privosegtor could position it as a first-of-its-kind treatment for optic neuritis, addressing a significant unmet medical need. The company's strategic sponsorship of the conference highlights its commitment to advancing scientific progress in neuro-ophthalmology, potentially setting a new standard for therapeutic interventions in this field.
What we're watching
- Clinical Efficacy
- How the Phase 2 data will influence the progression of Privosegtor through the PIONEER registrational program.
- Regulatory Pathway
- Whether the Breakthrough Therapy designation will accelerate Privosegtor's approval process for optic neuritis.
- Market Potential
- The pace at which Privosegtor could expand into other neuro-ophthalmic and neurological indications.